David has spent over 30 years in the healthcare industry, including 14 years in sales and marketing with Glaxo Wellcome, Cephalon Inc, Oxford Molecular Group Plc, and latterly 8 years with SR One (GSK’s Corporate Venture Fund). In between these two periods with GSK, David spent 12 years at Board level as Chief Business Officer of Argenta Discovery, The Automation Partnership and BioFocus Plc (prior to the divestment to Galapagos NV where he stayed with the business). David rejoined GSK’s SR One in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and in parallel investing in early stage life science companies. He has divested a number of R&D operations and drug delivery technologies. He led the team that divested GSK’s Opiates business in Australia in 2015.